An appeals panel ruled that the FDA improperly expanded access to the abortion pill mifepristone over the past seven years but left in place the drug’s original approval, teeing up the issue for review by the Supreme Court.
Wall Street Journal
An appeals panel ruled that the FDA improperly expanded access to the abortion pill mifepristone over the past seven years but left in place the drug’s original approval, teeing up the issue for review by the Supreme Court.